R
Reata Pharmaceuticals Inc
F:2R3
Reata Pharmaceuticals Inc
F:2R3
Price:
161
EUR
Market Cap:
€6B
Balance Sheet
Balance Sheet Decomposition
Reata Pharmaceuticals Inc
Reata Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
Reata Pharmaceuticals Inc
Reata Pharmaceuticals Inc
Balance Sheet
Reata Pharmaceuticals Inc
Reata Pharmaceuticals Inc
Currency: USD
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
177
|
88
|
42
|
85
|
130
|
338
|
664
|
818
|
590
|
42
|
|
| Cash Equivalents |
177
|
88
|
42
|
85
|
130
|
338
|
664
|
818
|
590
|
42
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
345
|
|
| Total Receivables |
11
|
15
|
32
|
0
|
0
|
0
|
0
|
22
|
0
|
0
|
|
| Other Current Assets |
5
|
4
|
3
|
3
|
3
|
5
|
5
|
7
|
6
|
10
|
|
| Total Current Assets |
192
|
107
|
77
|
87
|
133
|
342
|
669
|
847
|
596
|
398
|
|
| PP&E Net |
5
|
3
|
1
|
1
|
1
|
1
|
12
|
10
|
138
|
116
|
|
| PP&E Gross |
0
|
0
|
0
|
1
|
1
|
1
|
12
|
10
|
138
|
116
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
13
|
12
|
13
|
13
|
14
|
15
|
16
|
|
| Other Long-Term Assets |
32
|
16
|
1
|
1
|
2
|
2
|
1
|
0
|
0
|
0
|
|
| Total Assets |
230
N/A
|
126
-45%
|
79
-37%
|
89
+13%
|
135
+52%
|
345
+155%
|
682
+98%
|
858
+26%
|
735
-14%
|
514
-30%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
2
|
1
|
4
|
4
|
2
|
5
|
2
|
5
|
14
|
19
|
|
| Accrued Liabilities |
1
|
4
|
4
|
6
|
13
|
15
|
27
|
17
|
17
|
16
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
1
|
0
|
150
|
73
|
0
|
0
|
|
| Other Current Liabilities |
112
|
54
|
54
|
50
|
32
|
36
|
13
|
24
|
23
|
24
|
|
| Total Current Liabilities |
115
|
58
|
61
|
60
|
48
|
56
|
192
|
119
|
54
|
59
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
18
|
79
|
222
|
0
|
0
|
0
|
|
| Other Liabilities |
392
|
342
|
291
|
245
|
216
|
195
|
12
|
321
|
495
|
521
|
|
| Total Liabilities |
507
N/A
|
400
-21%
|
352
-12%
|
304
-14%
|
282
-7%
|
330
+17%
|
426
+29%
|
440
+3%
|
549
+25%
|
580
+6%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
282
|
282
|
283
|
289
|
337
|
420
|
711
|
958
|
1 256
|
1 568
|
|
| Additional Paid In Capital |
6
|
8
|
10
|
74
|
190
|
436
|
967
|
1 376
|
1 442
|
1 502
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
277
N/A
|
274
+1%
|
273
+0%
|
215
+21%
|
147
+32%
|
15
N/A
|
257
+1 590%
|
417
+62%
|
186
-55%
|
66
N/A
|
|
| Total Liabilities & Equity |
230
N/A
|
126
-45%
|
79
-37%
|
89
+13%
|
135
+52%
|
345
+155%
|
682
+98%
|
858
+26%
|
735
-14%
|
514
-30%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
20
|
20
|
20
|
22
|
26
|
30
|
33
|
36
|
36
|
37
|
|
Switch to:
Switch to:
See Also
Discover More
